CAJ | 학술논문

目的评估抗真菌药物布替奈芬对眼部致病真菌的体外抗菌活性.方法实验研究.参照美国临床和实验室标准化研究所制定的M38-A方案,用微量液基稀释法对260株(15属29种)眼部分离真菌进行布替奈芬体外抗菌活性研究,并与那他霉素、二性霉素B及氟康唑进行对比.布替奈芬的实验浓度范围0.008～16.000 mg/L,那他霉素和二性霉素B的实验浓度范围0.031～16.000 mg/L.,氟康唑的实验浓度范围0.5～256.0 mg/L.那他霉素和二性霉素B取100%的真菌生长抑制为最低抑菌浓度(MIC),布替奈芬和氟康唑取75%的真菌生长抑制为MIC,,应用SPSS13.0统计学软件对数据进行处理,采用描述性统计分析方法计算4种药物对实验菌的MIC均数、MIC范围、MIC_(50)及MIC_(90).结果布替奈芬、那他霉素、二性霉素B、氟康唑对镰孢菌属的MIC_(90)分别为4、8、2、512 mg/L;对曲霉菌属的MIC_(90)分别为0.063、32.000、2.000、256.000mg/L;对互隔交链孢霉的MIC_(90)分别为0.5、8.0、2.0、128.0 mg/L;对新月弯孢霉的MIC_(90)分别为0.125、2.000、0.500、4.000 mg/L;对罕见眼部致病真菌的MIC_(90)分别为1、4、1、256 mg/L.结论布替奈芬对眼部分离真菌具有广谱抗菌活性,对曲霉菌属、互隔交链孢霉及新月弯孢霉的抗菌活性尤强,提示开发布替条芬滴眼剂型对临床治疗真菌性角膜炎具有重要意义.
목적 평고항진균약물포체내분대안부치병진균적체외항균활성.방법 실험연구.삼조미국림상화실험실표준화연구소제정적M38-A방안,용미량액기희석법대260주(15속29충)안부분리진균진행포체내분체외항균활성연구,병여나타매소、이성매소B급불강서진행대비.포체내분적실험농도범위0.008～16.000 mg/L,나타매소화이성매소B적실험농도범위0.031～16.000 mg/L.,불강서적실험농도범위0.5～256.0 mg/L.나타매소화이성매소B취100%적진균생장억제위최저억균농도(MIC),포체내분화불강서취75%적진균생장억제위MIC,,응용SPSS13.0통계학연건대수거진행처리,채용묘술성통계분석방법계산4충약물대실험균적MIC균수、MIC범위、MIC_(50)급MIC_(90).결과 포체내분、나타매소、이성매소B、불강서대렴포균속적MIC_(90)분별위4、8、2、512 mg/L;대곡매균속적MIC_(90)분별위0.063、32.000、2.000、256.000mg/L;대호격교련포매적MIC_(90)분별위0.5、8.0、2.0、128.0 mg/L;대신월만포매적MIC_(90)분별위0.125、2.000、0.500、4.000 mg/L;대한견안부치병진균적MIC_(90)분별위1、4、1、256 mg/L.결론 포체내분대안부분리진균구유엄보항균활성,대곡매균속、호격교련포매급신월만포매적항균활성우강,제시개발포체조분적안제형대림상치료진균성각막염구유중요의의.
Objective To investigate antifungal activity of butenafine in comparison with that of natamycin, amphotericin B and fluconazole against ocular pathogenic filmentous fungi in vitro.Methods It was an experimental study.Susceptibility tests were performed against 260 isolates of ocular pathogenic filmentous fungi by broth dilution antifungal susceptibility test of filamentous fungi approved by the Clinical and Laboratory Standards Institute (CLSI) M38-A document The isolates included Fusarium spp.(136) , Aspergillus spp.(98), Alternaria alternata (9), Curmdaria lunata (3), and unusual ocular pathogens (14).Final concentration ranged from 0.008 to 16.000 mg/L for butenafine, from 0.031 to 16.000 mg/L for amphotericin B and natamycin, and from 0.5 to 256.0 mg/L for fluconazole.Following incubation at 35 ℃ for 48 h, minimal inhibitory concentration (MIC) was determined according to the CLSI M38-A document For amphotericin B and natamycin, the MIC was defined as the lowest drug concentration that prevented any discernible growth.For butenafine and fluconazole, the MIC was defined as the lowest concentration in which an approximately 75% reduction compared to the growth of the control was observed.Candida parapsilosis ATCC22019 was used as quality control strains to validated the results.Mean MIC and MIC range, the MIC at which 50% of the isolates tested were inhibited (MIC_(50)) and the MIC at which 90% of the isolates tested were inhibited (MIC_(90)) , were provided for all the isolates tested by using descriptive statistical analysis with the statistical SPSS package (version 13.0).Results MIC_(90) of butenafine, natamycin, amphotericin B and fluconazole were 4,8,2 and 512 mg/L for Fusarium spp., respectively; 0.063, 32.000, 2.000 and 256.000 mg/L for Aspergillus spp., respectively; 0.5, 8.0, 2.0 and 128.0 mg/L for Alternaria alternat, respectively; 0.125, 2.000, 0.500 and 4.000 mg/L for Curvularia lunata, respectively; and 1,4,1 and 256 mg/L for unusual ocular pathogens, respectively.Conclusions Butenafine exhibits potent antifungal activity against a wide variety of ocular pathogenic fungi, especially for Aspergilllus spp., Alternaria altemata, Curvularia lunata, and some unusual ocular pathogens and may have a role in future studies of antifungal eye drops and treating fungal keratitis.